TITLE

Liraglutide: a guide to its use in type 2 diabetes mellitus

PUB. DATE
September 2010
SOURCE
Drugs & Therapy Perspectives;Sep2010, Vol. 26 Issue 9, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Liraglutide, an analogue of glucagon-like peptide-1, is indicated for the treatment of type 2 diabetes mellitus. In clinical trials, once-daily subcutaneous liraglutide improved glycaemic control as monotherapy or in combination with one or two oral antidiabetic drugs. It also was associated with improvements in pancreatic β-cell function, weight loss and a low risk of hypoglycaemia.
ACCESSION #
55274706

 

Related Articles

  • Incretin-based therapies for type 2 diabetes. Capaldi, Brenda // Practice Nursing;Oct2012, Vol. 23 Issue 10, p508 

    The article discusses the use of incretin-based therapies for people with type 2 diabetes. The number of people with type 2 diabetes is increasing and controlling blood glucose levels in these patients can be challenging. Incretin-based glucagonlike peptide (GLP)-1 receptor agonists and...

  • 2016 - In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c. Gonzales, Krista; Gandhi, Gunjan Y.; Lingvay, I. // ACP Journal Club;10/18/2016, Vol. 165 Issue 8, p1 

    Question In patients with uncontrolled type 2 diabetes treated with high doses of insulin, what is the effect of adding liraglutide on glycated hemoglobin (Hb) A[sub 1c] levels? Methods Design Randomized placebo-controlled trial. ClinicalTrials.gov NCT01505673. Allocation {Concealed}*.†...

  • Efficacy of secondline therapies added to metformin in T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p143 

    The article discusses a study conducted by S. C. Liu, Y. K. Tu, M. N. Chien and colleagues comparing the efficacy of second-line antidiabetes drugs in people with T2D taking metformin.

  • Diabetes masterclass: Optimising therapies for type 2 diabetes. Bostock-Cox, Beverley // Practice Nurse;8/14/2015, Vol. 45 Issue 8, p12 

    The article takes a look at the drugs used to minimize risk for patients with type 2 diabetes focusing primarily on those used to improve glycaemic control. Topics the article's objectives for people to understand the basic mode of action of drugs used to treat hyperglycaemia, evaluate the...

  • FFAR1 found to be a viable therapeutic target in the treatment of T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p144 

    The article discusses research being done on free fatty acid receptor 1 (FFAR1) as a viable target for treatment of type 2 diabetes (T2D). It references the study "TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial,"...

  • A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. White, Judith L.; Buchanan, Patricia; Jia Li; Frederich, Robert // BMC Endocrine Disorders;2014, Vol. 14 Issue 1, p1 

    Background To compare the safety and efficacy of saxagliptin 2.5 mg twice daily (BID) versus placebo add-on therapy to metformin immediate release (IR) in patients with type 2 diabetes and inadequate glycemic control with metformin alone. Methods This multicenter, 12-week, double-blind,...

  • Exenatide + rosiglitazone added to metformin.  // Clinical Oncology Alert;Aug2010 Supplement, p16 

    The article discusses research being done on the effect of exenatide (EXE) and rosiglitazone (ROS) when added to metformin to control glucose in patients with type 2 diabetes (DM2) in reference to a study by R. A. DeFronzo et al. published in the 2010 issue of "Diabetes Care."

  • Exenatide + rosiglitazone added to metformin.  // Clinical Cardiology Alert;Aug2010 Supplement, p16 

    The article discusses research being done on the efficacy of exenatide and rosiglitazone added to metformin for controlling glucose, with reference to a study by R. A. DeFronzo and colleagues, published in the 2010 issue of the journal "Diabetes Care."

  • Exenatide + rosiglitazone added to metformin. Kuritzky, Louis // Critical Care Alert;Aug2010 Primary Care Supp, p16 

    The article presents information on the treatment of type 2 diabetes with adequate lifestyle and metformin.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics